Generic Onzetra Xsail Availability

Last updated on May 7, 2025.

Onzetra Xsail is a brand name of sumatriptan, approved by the FDA in the following formulation(s):

ONZETRA XSAIL (sumatriptan succinate - powder;nasal)

Manufacturer: CURRAX
Approval date: January 27, 2016
Strength(s): EQ 11MG BASE ^[RLD]

Is there a generic version of Onzetra Xsail available?

No. There is currently no therapeutically equivalent version of Onzetra Xsail available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Onzetra Xsail. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Nasal delivery devices
Patent 10,076,614
Issued: September 18, 2018
Inventor(s): Djupesland Per Gisle & Gordon Joseph & Leclerc Michael & Mahmoud Ramy A & Siwinski Shane
Assignee(s): OptiNose AS
A nasal delivery device for delivering substance to a nasal cavity of a subject comprises: a housing (); a nosepiece () for fitting to a nasal cavity of the subject; a mouthpiece () through which the subject in use exhales; and a flexible coupling () which couples the mouthpiece to the housing, wherein the flexible coupling provides for asymmetric translation of the mouthpiece relative to the nosepiece.
Patent expiration dates:
- October 20, 2034
  ✓
  Drug product
Nasal delivery
Patent 10,076,615
Issued: September 18, 2018
Inventor(s): Djupesland Per Gisle & Sheldrake Colin David
Assignee(s): OptiNose AS
A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece for fitting to a nostril of a subject, wherein the nosepiece comprises a tip element which includes a delivery aperture from which substance is in use delivered into the nasal cavity, and the tip element is at least in part tapered such as to be inclined to a longitudinal axis of the nosepiece, with the delivery aperture extending both laterally across the tip element and along a longitudinal extent of the tip element; a nozzle through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity; and a delivery unit for delivering substance through the nozzle of the nosepiece.
Patent expiration dates:
- July 30, 2029
  ✓
  Patent use: ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
- July 30, 2029
  ✓
  Patent use: TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
- July 30, 2029
  ✓
  Patent use: METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
Nasal delivery
Patent 10,124,132
Issued: November 13, 2018
Inventor(s): Djupesland Per Gisle
Assignee(s): OptiNose AS
A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit including a nosepiece for fitting to a nostril of a subject and a nozzle through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity, wherein at least a tip element of the nosepiece has, at least in one configuration, an elongate lateral section which has a longer dimension in a first, sagittal direction than a second direction orthogonal to the sagittal direction, such that, when the nosepiece is inserted in the nasal cavity of the subject, the longer dimension of the nosepiece acts to engage lower and upper surfaces of the nasal cavity, preferably at the nasal valve, and expand the same in the sagittal plane; and a delivery unit for delivering substance through the nozzle of the nosepiece.
Patent expiration dates:
- March 6, 2027
  ✓
  Patent use: ACUTE TREATMENT OF MIGRAINE
  ✓
  Drug product
- March 6, 2027
  ✓
  Patent use: ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
  ✓
  Drug product
- March 6, 2027
  ✓
  Patent use: TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
  ✓
  Drug product
Nasal delivery devices
Patent 10,398,859
Issued: September 3, 2019
Inventor(s): Djupesland Per Gisle & Hafner Roderick Peter & Sheldrake Colin David
Assignee(s): OptiNose AS
A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a container-receiving unit comprising a container chamber for receiving a substance-containing container which contains substance to be delivered to the nasal cavity of the subject, the container chamber including an inlet and an outlet; a nosepiece unit including a nosepiece for fitting to a nasal cavity of the subject and being in fluid communication with the outlet of the container chamber; a mouthpiece unit including a mouthpiece in fluid communication with the inlet of the container chamber and through which the subject in use exhales, such as to entrain substance from the container and deliver the same through the nosepiece; and moisture-mitigation means for mitigating an effect of moisture in an exhaled breath on the entrainment of substance from the container, which means are provided, for example, by providing the container in a replaceable container-containing member, by a pressure-sensitive valve which normally closes the fluid connection between the container chamber and the mouthpiece, and a temperature regulator upstream of the container chamber.
Patent expiration dates:
- December 19, 2027
  ✓
  Drug product
Nasal administration
Patent 10,478,574
Issued: November 19, 2019
Inventor(s): Djupesland Per Gisle & Hafner Roderick Peter
Assignee(s): OptiNose AS
A delivery device for and method of providing for delivery of substance to the central nervous system (CNS) of a subject, the delivery device comprising: a nosepiece unit () for insertion into a nasal airway () of a subject and comprising an outlet unit () which includes a nozzle () for delivering substance into the nasal airway of the subject; and a substance supply unit which is operable to deliver a dose of substance to the nozzle: wherein the delivery device is configured such that at least 30% of the dose as initially deposited in the nasal airway is deposited in an upper posterior region of the nasal airway, thereby providing a CNS concentration of the substance, and hence CNS effect, which is significantly greater than that which would be predicted from a counterpart blood plasma concentration of the substance.
Patent expiration dates:
- November 4, 2033
  ✓
  Patent use: METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
Nasal administration
Patent 10,722,667
Issued: July 28, 2020
Inventor(s): Djupesland Per Gisle & Hafner Roderick Peter
Assignee(s): OptiNose AS
A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.
Patent expiration dates:
- December 30, 2028
  ✓
  Drug product
Powder delivery devices
Patent 11,571,531
Issued: February 7, 2023
Inventor(s): Djupesland; Per Gisle et al.
Assignee(s): OptiNose Inc. (Yardley, PA)
A nasal delivery device for delivering substance to a nasal cavity of a subject, the delivery device comprising: a substance supply unit for supplying a dose of substance to be delivered to the nasal cavity of the subject, the substance supply unit including an inlet and an outlet; a nosepiece unit including a nosepiece for fitting to a nasal cavity of the subject and being in fluid communication with the outlet of the substance supply unit; and a mouthpiece unit including a mouthpiece in fluid communication with the inlet of the substance supply unit and through which the subject in use exhales such as to entrain substance from the container chamber and deliver the same through the nosepiece, and at least one temperature modifier for reducing a temperature of the exhaled air flow such as to reduce the absolute humidity thereof.
Patent expiration dates:
- February 23, 2026
  ✓
  Patent use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
Nasal devices
Patent 7,975,690
Issued: July 12, 2011
Inventor(s): Djupesland; Per Gisle
Assignee(s): OptiNose AS (Oslo, NO)
The present invention relates to a nasal delivery device for and a method of delivering a substance, in particular one of a liquid, as a suspension or solution, or a powder containing a medicament, especially systemic or topical pharmaceuticals, or a vaccine to the nasal airway of a subject.
Patent expiration dates:
- August 18, 2025
  ✓
  Patent use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
  ✓
  Drug product
Nasal delivery
Patent 8,550,073
Issued: October 8, 2013
Inventor(s): Djupesland Per Gisle
Assignee(s): OptiNose AS
A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece unit () including a nosepiece () for fitting to a nostril of a subject and a nozzle () through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity, wherein at least a tip element of the nosepiece has, at least in one configuration, an elongate lateral section which has a longer dimension in a first, sagittal direction than a second direction orthogonal to the sagittal direction, such that, when the nosepiece is inserted in the nasal cavity of the subject, the longer dimension of the nosepiece acts to engage lower and upper surfaces of the nasal cavity, preferably at the nasal valve, and expand the same in the sagittal plane; and a delivery unit () for delivering substance through the nozzle of the nosepiece.
Patent expiration dates:
- October 22, 2029
  ✓
  Drug product
Nasal delivery devices
Patent 8,590,530
Issued: November 26, 2013
Inventor(s): Djupesland Per Gisle & Hafner Roderick Peter & Sheldrake Colin David
Assignee(s): OptiNose AS
A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a container-receiving unit comprising a container chamber for receiving a substance-containing container which contains substance to be delivered to the nasal cavity of the subject, the container chamber including an inlet and an outlet; a nosepiece unit including a nosepiece for fitting to a nasal cavity of the subject and being in fluid communication with the outlet of the container chamber; a mouthpiece unit including a mouthpiece in fluid communication with the inlet of the container chamber and through which the subject in use exhales, such as to entrain substance from the container and deliver the same through the nosepiece; and moisture-mitigation means for mitigating an effect of moisture in an exhaled breath on the entrainment of substance from the container.
Patent expiration dates:
- September 15, 2025
  ✓
  Patent use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
  ✓
  Drug product
Nasal administration
Patent 8,875,704
Issued: November 4, 2014
Inventor(s): Djupesland Per Gisle & Hafner Roderick Peter
Assignee(s): Optinose AS
A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.
Patent expiration dates:
- April 7, 2028
  ✓
  Patent use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
  ✓
  Drug product
Powder delivery devices
Patent 8,899,229
Issued: December 2, 2014
Inventor(s): Djupesland Per Gisle & Hafner Roderick Peter & Sheldrake Colin David
Assignee(s): OptiNose AS
A nasal delivery device for delivering substance to a nasal cavity of a subject, the delivery device comprising: a substance supply unit for supplying a dose of substance to be delivered to the nasal cavity of the subject, the substance supply unit including an inlet and an outlet; a nosepiece unit including a nosepiece for fitting to a nasal cavity of the subject and being in fluid communication with the outlet of the substance supply unit; and a mouthpiece unit including a mouthpiece in fluid communication with the inlet of the substance supply unit and through which the subject in use exhales such as to entrain substance from the container chamber and deliver the same through the nosepiece, and at least one temperature modifier for reducing a temperature of the exhaled air flow such as to reduce the absolute humidity thereof.
Patent expiration dates:
- August 18, 2030
  ✓
  Drug product
Nasal delivery
Patent 8,978,647
Issued: March 17, 2015
Inventor(s): Djupesland Per Gisle & Sheldrake Colin David
Assignee(s): Optinose, AS
A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nosepiece for fitting to a nostril of a subject, wherein the nosepiece comprises a tip element which includes a delivery aperture from which substance is in use delivered into the nasal cavity, and the tip element is at least in part tapered such as to be inclined to a longitudinal axis of the nosepiece, with the delivery aperture extending both laterally across the tip element and along a longitudinal extent of the tip element; a nozzle through which substance is in use delivered, preferably substantially axially to a longitudinal axis of the nosepiece, to the respective nasal cavity; and a delivery unit for delivering substance through the nozzle of the nosepiece.
Patent expiration dates:
- December 6, 2030
  ✓
  Drug product
Nasal delivery devices
Patent 9,108,015
Issued: August 18, 2015
Inventor(s): Djupesland Per Gisle & Hafner Roderick Peter & Sheldrake Colin David
Assignee(s): OptiNose AS
A nasal delivery device for and method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a container-receiving unit comprising a container chamber for receiving a substance-containing container which contains substance to be delivered to the nasal cavity of the subject, the container chamber including an inlet and an outlet; a nosepiece unit including a nosepiece for fitting to a nasal cavity of the subject and being in fluid communication with the outlet of the container chamber; a mouthpiece unit including a mouthpiece in fluid communication with the inlet of the container chamber and through which the subject in use exhales, such as to entrain substance from the container and deliver the same through the nosepiece; and moisture-mitigation means for mitigating an effect of moisture in an exhaled breath on the entrainment of substance from the container, which means are provided, for example, by providing the container in a replaceable container-containing member, by a pressure-sensitive valve which normally closes the fluid connection between the container chamber and the mouthpiece, and a temperature regulator upstream of the container chamber.
Patent expiration dates:
- September 15, 2025
  ✓
  Drug product
Nasal administration
Patent 9,649,456
Issued: May 16, 2017
Inventor(s): Djupesland Per Gisle & Hafner Roderick Peter
Assignee(s): OptiNose AS
A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece () for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit () which is operable to deliver the powdered substance through the nosepiece ().
Patent expiration dates:
- October 21, 2030
  ✓
  Patent use: ACUTE TREATMENT OF MIGRAINE
  ✓
  Drug product
- October 21, 2030
  ✓
  Patent use: ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
  ✓
  Drug product
- October 21, 2030
  ✓
  Patent use: TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
  ✓
  Drug product

More about Onzetra Xsail (sumatriptan)

Patient resources

Other brands

Imitrex, Tosymra, Sumavel DosePro, Zembrace SymTouch, ... +2 more

Professional resources

Other brands

Imitrex, Tosymra, Sumavel DosePro, Zembrace SymTouch, Zecuity

Related treatment guides

Migraine

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

5 Reviews